[1] Natarajan A, Beena PM, Devnikar AV,et al. A systemic review on tuberculosis. Indian J Tuberc, 2020, 67(3):295-311. [2] Snow KJ, Cruz AT, Seddon JA,et al. Adolescent tuberculosis. Lancet Child Adolesc Health, 2020, 4(1):68-79. [3] Pan Y, Tang P, Cao J,et al. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction. Biochem Biophys Res Commun, 2020, 533(4):1512-1518. [4] Lei X, Zhang J, Xu Q,et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res, 2021, 49(8):3000605211039810. [5] Islam A, Mishra A, Siddiqui MA,et al. Recapitulation of evidence of phytochemical, pharmacokinetic and biomedical application of silybin. Drug Res (Stuttg), 2021, 71(9):489-503. [6] Zhang Y, Biao Y, Chu X,et al. Protective effect of Chushizi (Fructus Broussonetiae) on acetaminophen-induced rat hepatitis by inhibiting the Toll-like receptor 3/c-Jun N-terminal kinase/c-jun/c-fos/janus protein tyrosine kinase/activators of transcription 3 pathway. J Tradit Chin Med, 2020, 40(6):965-973. [7] 中华医学会结核病学分会.抗结核药物性肝损伤诊治指南(2019年版).中华结核和呼吸杂志,2019,42(5):343-356. [8] Banerjee R, Ali RAR, Wei SC, et al. Biologics for themanagement of inflammatory bowel disease: A review in tuberculosis-endemic countries. Gut Liver, 2020, 14(6):685-698. [9] Liu X, Ren S, Zhang J,et al. The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. Ann Palliat Med, 2021, 10(6):6518-6534. [10] Moosa MS, Maartens G, Gunter H,et al. A randomized controlled trial of intravenous N-acetylcysteine in the management of anti-tuberculosis drug-induced liver injury. Clin Infect Dis, 2021, 73(9):e3377-e3383. [11] 魏明禄, 刘建民, 陈南清,等.滋肾益肝方联合多烯磷脂酰胆碱治疗抗结核药物所致急性肝损伤的有效性与安全性研究.中华中医药学刊,2018,36(1):45-48. [12] Zhang R, Xu D, Zhang Y,et al. Silybin restored CYP3A expression through the sirtuin 2/nuclear factor κ-B pathway in mouse nonalcoholic fatty liver disease. Drug Metab Dispos, 2021, 49(9):770-779. [13] Cui S, Pan XJ, Ge CL,et al. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. Chin J Nat Med, 2021, 19(6):401-411. [14] Duan RL, Sun X, Liu J,et al. Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility. Acta Pharmacol Sin, 2011, 32(1):108-115. [15] Li X, Wang Y, Xing Y,et al. Changes of gut microbiota during silybin-mediated treatment of high-fat diet-induced non-alcoholic fatty liver disease in mice. Hepatol Res, 2020, 50(1):5-14. [16] Naidoo K, Hassan-Moosa R, Mlotshwa P,et al. High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: Results from the starting antiretroviral therapy at three points in TB trial. Clin Infect Dis, 2020, 70(12):2675-2682. [17] Zhang D, Hao J, Hou R,et al. The role of NAT2 polymorphism and methylation in anti-tuberculosis drug-induced liver injury in Mongolian tuberculosis patients. J Clin Pharm Ther, 2020, 45(3):561-569. [18] Ambade A, Lowe P, Kodys K,et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology, 2019, 69(3):1105-1121. [19] Sun Y, Gu J, Liu R,et al. IL-2/IL-6 ratio correlates with liver function and recovery in acute liver injury patients. APMIS, 2019, 127(6):468-474. [20] Serrya MS, Nader MA, Abdelmageed ME. Hepatoprotective effect of the tyrosine kinase inhibitor nilotinib against cyclosporine-A induced liver injury in rats through blocking the Bax/Cytochrome C/caspase-3 apoptotic signaling pathway. J Biochem Mol Toxicol, 2021, 35(6):1-13. [21] 刘俊平, 郭新忠, 李晓敏,等.水飞蓟宾胶囊对慢性HBV感染患者肝纤维化Wnt/β-catenin信号通路的影响.中华医院感染学杂志,2022,32(3):336-340. [22] Santos EA, Gonçalves JCS, Fleury MK,et al. Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST. Braz J Infect Dis, 2019, 23(6):381-387. [23] Jiang F, Yan H, Liang L,et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int, 2021, 41(7):1565-1575. [24] El-Hussieny M, Mohammed EM, Zenhom NM, et al. Possible role of TGF-β1, MMP-2, E-CAD, β-catenin and antioxidants in pathogenesis of placenta accreta. Fetal Pediatr Pathol, 2021, 40(3):222-232. [25] Sri Iswari R, Dafip M, Purwantoyo E. Malondialdehyde (MDA)production in atherosclerosis supplemented with steamed tomato. Pak J Biol Sci, 2021, 24(3):319-325. [26] 陈靓, 黄强, 刘三海,等.五苓散联合多烯磷脂酰胆碱对非酒精性脂肪性肝病的临床观察.中华中医药学刊,2020,38(6):190-193. |